Skip to main content

Alnylam Pharmaceuticals Aktie - Fundamentalanalyse - Dividendenrendite KGV

Alnylam Pharmaceuticals (ISIN: US02043Q1076, WKN: A0CBCK) Kursdatum: 22.09.2017 Kurs: 113,800 USD
Beschreibung Daten
Symbol ALNY
Marktkapitalisierung 9.741.280.256,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Pharma
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet
Letztes Bilanz Update 15.02.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 22.09.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
-26,17 -31,66 0,00% -32,47 72,87 -23,76 206,56 10,59

Firmenbeschreibung

 

 

 

 

 

12.

QUARTERLY FINANCIAL

DATA (UNAUDITED)

 

 

 

The following information

has been derived from unaudited consolidated financial statements

that, in the opinion of management, include all recurring

adjustments necessary for a fair statement of such

information.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months

Ended

 

 

 

 

 

March 31,

2015

 

 

June 30,

2015

 

 

September 30,

2015

 

 

December 31,

2015

 

 

 

 

 

(In thousands, except

per share data)

 

 

 

 

Revenues

 

 

$

18,537

  

 

$

8,685

  

 

$

6,324

  

 

$

7,551

  

 

 

 

Operating

expenses

 

 

 

70,759

  

 

 

81,629

  

 

 

84,654

  

 

 

100,063

  

 

 

 

Net loss

 

 

$

(50,777

 

$

(71,783

 

$

(76,792

 

$

(90,721

 

 

 

Net loss per common share

— basic and diluted

 

 

$

(0.62

 

$

(0.85

 

$

(0.91

 

$

(1.07

 

 

 

Weighted-average common

shares — basic and diluted

 

 

 

82,074

  

 

 

84,353

  

 

 

84,633

  

 

 

84,871

  

 

 

 

 

 

 

 

 

Three Months

Ended

 

 

 

 

 

March 31,

2014

 

 

June 30,

2014

 

 

September 30,

2014

 

 

December 31,

2014

 

 

 

 

 

(In thousands, except

per share data)

 

 

 

 

Revenues

 

 

$

8,275

  

 

$

7,295

  

 

$

10,972

  

 

$

24,019

  

 

 

 

Operating

expenses

 

 

 

277,339

  

 

 

52,300

  

 

 

56,171

  

 

 

69,731

  

 

 

 

Net loss

 

 

$

(250,943

 

$

(44,074

 

$

(43,989

 

$

(21,389

 

 

 

Net loss per common share

— basic and diluted

 

 

$

(3.70

 

$

(0.58

 

$

(0.58

 

$

(0.28

 

 

 

Weighted-average common

shares — basic and diluted

 

 

 

67,786

  

 

 

75,835

  

 

 

76,408

  

 

 

76,957

  

 

 

 

Operating expenses for

the three months ended March 31, 2014 include a $224.7 million

charge to in-process research and development expense in connection

with the purchase of the Sirna RNAi assets from Merck. During the

three months ended June 30, 2014, we recorded a credit of $3.9

million to in-process research and development expense, resulting

in $220.8 million in-process research and development expense

recorded for the year ended December 31, 2014 as a result of

this asset acquisition. See Note 3, “Significant

Agreements,” for further information.

 

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr.